Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Development
AbbVie and Capsida expand genetic medicine collaboration, target eye diseases
by Gina Vitale
March 4, 2023
| A version of this story appeared in
Volume 101, Issue 8
AbbVie and Capsida Biotherapeutics will collaborate to develop three genetic medicine programs for eye diseases, building on a partnership announced in 2021 to develop gene therapies for central nervous system (CNS) disease targets. Capsida will get $70 million as part of the deal and may earn up to $595 million in option fees and R&D milestones. In January, Capsida announced a gene therapy collaboration with the Eli Lilly and Company subsidiary Prevail Therapeutics.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X